AstraZeneca Half-Year 2018 Results
AstraZeneca's Half-Year 2018 results announcement will be published and available here at 07:00 UK time on Thursday 26th July 2018.
A webcast for investors and analysts will take place at 12:30 UK time on the day. Please register to participate.
Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
Transparency Directive Voting Rights and Capital
Lynparza approved in Japan for BRCA-mutated metastatic breast cancer
Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer
Bydureon receives positive EU CHMP opinion for new BCise device for patients with type-2 diabetes
Agreement with Luye Pharma Group for rights to Seroquel and Seroquel XR in the UK, China and other international markets completed
Our Annual Report provides a wide range of information about our global business.
Answers to frequently asked shareholder questions.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development